Experimental cocktail aims to outsmart Drug-Resistant melanoma
Disease control
Recruiting now
This early-stage trial tests whether adding nilotinib to standard BRAF/MEK inhibitor therapy can help people with advanced melanoma whose cancer has stopped responding to treatment. About 30 participants will receive the drug combination to see if it is safe and tolerable. The go…
Phase: PHASE1 • Sponsor: Rina Plattner • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC